Description
ADEMPAS (RIOCIGUAT)
First action · last action
2015-11-10 · 2018-01-25
Transactions
2
First transaction's obligation
$16,840
Base + all options value (sum of deltas)
$11,227
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
—
Offers received
1
SDVOSB flag on record
No
Parent IDV
V797P2202D
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 2 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2015-11-10+$16,840= $16,840
- Mod P000012018-01-25-$5,613= $11,227
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2015-11-10 | +$16,840 | $16,840 | ADEMPAS (RIOCIGUAT) |
| Mod P00001· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2018-01-25 | −$5,613 | $11,227 | ADEMPAS (RIOCIGUAT) |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI V1EVGCK7XES8)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C25626N0492 | 256-NETWORK CONTRACT OFFICE 16 (36C256) · 6505 · DRUGS AND BIOLOGICALS | $386,860 | FY2026 |
| 36C26226F0163 | 262-NETWORK CONTRACT OFFICE 22 (36C262) · 6505 · DRUGS AND BIOLOGICALS | $181,386 | FY2026 |
| 36C26026F0086 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $80,663 | FY2026 |
| 36C26126N0199 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $101,567 | FY2026 |
| 36C25626N0126 | 256-NETWORK CONTRACT OFFICE 16 (36C256) · 6505 · DRUGS AND BIOLOGICALS | $214,783 | FY2026 |
| 36E79725A0028 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2025 |
Other recipients under 3650 from 248-NETWORK CONTRACT OFFICE 8 (36C248) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C24823N0035 | CARDINAL HEALTH 414, LLC | 248-NETWORK CONTRACT OFFICE 8 (36C248) | $105,612 | FY2023 |
| 36C24820F0103 | CSL BEHRING L.L.C. | 248-NETWORK CONTRACT OFFICE 8 (36C248) | $86,048 | FY2020 |
| 36C24819N1050 | CSL BEHRING L.L.C. | 248-NETWORK CONTRACT OFFICE 8 (36C248) | $78,932 | FY2019 |
| VA24817C0163 | MEDI-PHYSICS, INC. | 248-NETWORK CONTRACT OFFICE 8 (36C248) | $134,724 | FY2017 |
| VA24817F2026 | ASTELLAS PHARMA US, INC. | 248-NETWORK CONTRACT OFFICE 8 (36C248) | $243,162 | FY2017 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA24816F0274_3600_V797P2202D_3600 · retrieved 2026-09-26.